Clorox Price Target Cut Amid Consumption Concerns; Wells Fargo Adjusts Estimate

Wells Fargo has revised its price target for Clorox (CLX) from $142 to $135, citing weak consumption data and potential challenges in achieving growth. Analysts forecast an average target price of $145.36, with a high estimate of $189.00 and a low estimate of $119.00, implying an upside of 15.40% from the current price of $125.96.

Wells Fargo has revised its price target for Clorox (CLX) from $142 to $135, reflecting ongoing updates across various sectors, including Beverage, Food, and Household & Personal Care (HPC). The firm highlights weak consumption data as a primary concern and suggests that a potential adjustment to estimates could be on the horizon. Wells Fargo believes that until there is a clearer picture of consumption trends, Clorox (CLX) may face challenges in achieving growth in its stock valuation [1].

Based on the one-year price targets offered by 17 analysts, the average target price for Clorox Co (CLX) is $145.36 with a high estimate of $189.00 and a low estimate of $119.00. The average target implies an upside of 15.40% from the current price of $125.96 [1].

The consensus recommendation from 21 brokerage firms indicates an average brokerage recommendation of 3.0, indicating a "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies a Strong Buy, and 5 denotes a Sell [1].

GuruFocus estimates the GF Value for Clorox Co (CLX) in one year at $144.17, suggesting an upside of 14.46% from the current price of $125.96. GF Value is calculated based on historical multiples, past business growth, and future estimates of business performance [1].

Key business developments for Clorox Co (CLX) include achieving its 10th consecutive quarter of gross margin expansion, maintaining overall market share despite challenging conditions, and experiencing lower than expected sales due to weakened US consumer sentiment and macroeconomic uncertainties. The company continues to deliver organic sales growth and anticipates another year of strong earnings growth [1].

Positive points for Clorox Co (CLX) include its 10th consecutive quarter of gross margin expansion, maintaining overall market share despite a challenging consumer environment, and investing in its innovation pipeline and business transformation. The company has a strong portfolio of trusted brands and has successfully implemented ERP transitions in Canada and financial planning tools [1].

Negative points include weakened US consumer sentiment, macroeconomic and geopolitical uncertainties, headwinds from tariffs, retail destocking, and competitive promotional activity. These factors have impacted sales and are expected to continue impacting Q4 [1].

The company has seen several price target revisions by other analysts. JPMorgan Chase & Co. lowered their price target from $151.00 to $144.00 and set a "neutral" rating, while UBS Group lowered their target from $176.00 to $154.00 with a "neutral" rating. Evercore ISI set a $140.00 price target with an "underperform" rating, and Jefferies Financial Group decreased their objective from $167.00 to $145.00 with a "buy" rating. Barclays decreased their objective from $134.00 to $129.00 with an "underweight" rating [2].

Clorox's stock has a market capitalization of $15.47 billion, a debt-to-equity ratio of 13.07, a current ratio of 0.74, and a quick ratio of 0.44. The stock has a price-to-earnings ratio of 22.59 and a beta of 0.51. Institutional investors own 78.53% of the stock [2].

References:
[1] https://www.gurufocus.com/news/2965993/clorox-clx-faces-price-target-reduction-amid-consumption-concerns--clx-stock-news
[2] https://www.marketbeat.com/instant-alerts/wells-fargo-company-lowers-clorox-nyseclx-price-target-to-13500-2025-07-09/